Can we select NSCLC patients for immune checkpoint therapy?

11 / 38

Second-Line IO: Does PD-L1 worth?
Brahmer –NEJM 2015 * Borghaei – NEJM 2015 * Felip -ESMO 2017 * Herbst – Lancet Oncol 2016 * Herbst – ESMO 2016 * Herbst – ASCO 2017 * Rittmeyer – Lancet 2017
TC3/IC3: 20.5 vs. 8.9
PDL1 ≥ 50%:
14.9 vs. 17.3 vs. 8.2
HR 0.54, HR 0.50
Pembro - PD-L1 ≥1%
Nivo - All comers Nivo - All comers
Atezo - All comers